SUBJECT INDEX

preoperative in high-risk patients .......................... 1(E), 17, 689(L)
versus perioperative hemodilution ......................... 226
use of blood in .................................................. 648
safety of and reactions in ................................... 1(E), 17, 689(L)
schedule of optimal preoperative collection of .......... 190(L), 191(L)
transfusion and ................................................................
annotated bibliography on ........................................ 286
cancer recurrence and survival .................................. 31
postoperative infections .............................................. 27, 318, 517
risk of postoperative bacterial infection after .......... 517
use of blood drainage collection and transfusion device in ................................................................. 742

Autoreactivity and anti-idiotypic antibodies ................. 361

B
B-cell acute lymphocytic leukemia ............................. 790(L)
β-thromboglobulin ............................................... 500(E), 529, 534

Bacteria contamination of ...................................... 344
blood collected from drainage and transfusion device 742
frozen-thawed red cells ............................................. 3(E), 9, 381, 771
platelets ................................................................. 3(E), 9, 381, 771
red cells ................................................................. 86(L), 191(L), 199(E), 221, 597(E), 654, 658, 663, 667, 673, 742, 850
demonstration of clonal identity of ................................. 771
effect of transfusion on clearance of after burn injury 312
growth in platelets ................................................. 3(E), 9, 381, 771
in postoperative infection and transfusion ................. 27, 318, 517
removal by WBC reduction filtration.......................... 597(E), 654, 658, 663, 667, 673
stimulation of production of antibodies by ................ 790(L)
B-cell neoplasms, treatment of with anti-idiotypic antibodies 361
Benzoporphyrin derivative monocroic acid A, in virus inactivation ......................................................... 121
Bibliography on autologous transfusion .................. 286
Biocompatibility of WBC-reduction filters ................. 557
Bleeding time, correction after transfusion of ...... 3(E), 9, 381, 771
UVB-irradiated platelets ............................................ 402
Blood bank, role in ................................................. 272, 259(B)
marrow processing ................................................... 272
termology .............................................................. 88(L), 397(E), 494(L), 677, 695
Blood cell separator, collection of platelets by ......................................................... 624
two-stage procedure .................................................. 624
Blood collection staff, response to asking donors direct or indirect questions on high-risk behavior for HIV ......................................................... 446
systems and platelet activation .................................... 3(E), 9, 113, 386, 435, 500(E), 529, 534
Blood donors, see donors ........................................... 742
Blood drainage collection and transfusion device .......... 742
Blood group antigen, definition of .............................. 492(L)
collections ............................................................. 677
genesis ................................................................. 467
series ................................................................. 677
serology, future of .................................................. 98(E), 467, 492(L)
systems ............................................................... 677
terminology for use in electronic data processing equipment ......................................................... 677
Blood Products Advisory Committee recommended action and Y. enterocolitica ............................................. 199(E)
Blood shortages ......................................................... 797(E), 818
Blood supply, safety of ............................................... 465, 797(E), 818, 800(E), 868
Blood usage reviews .................................................. 253, 260, 648, 787(L), 873(L)
Bombay phenotype, molecular analysis of ................... 467
Bone marrow transplantation ........................................ 467

amphotericin B effect in ........................................... 7(E), 46
autologous ............................................................ 231
erythropoietin and ................................................... 272
prevention of CMV and GVHD in .............................. 272
processing role of blood bank in ................................... 272, 299(E)
standards for .......................................................... 299(E)
T-cell depletion and survival in .................................. 180
transfusion of marrow-derived RBCs after donation in ................................................. 231
unrelated-donor ....................................................... 180

Book review ............................................................ 508, 695, 793*

BTHC, see n-butyryl-tri-n-hexyl-citrate

Buffy coat method of platelet preparation ................. 3(E), 9, 113, 435
Bum injury and transfusion, effect on bacterial clearance ......................................................... 312

C
C4B null gene (C4B*Q0) .............................................. 145
CD4+ T-cell levels in ICL ........................................... 800(D)
Caffeinated beverage, effect on donation reactions .... 23
Calcium, role in platelet physiology .......................... 386
Canadians, risk of transfusion-associated GVHD in .... 691(L)
Cancer and protein column A spheresis in ......... 210
death and prophylactic platelet transfusion ................. 295(E), 377, 381
recurrence, survival and transfusion ......................... 31
role of blood bank in support in ............................... 272

CD44 ................................................................. 607
Cefotetan, IHA due to .................................................. 202(E), 266, 269
Cell production laboratories ...................................... 299(D)
receptors, anti-idiotypic antibodies as probes for .......... 361
Center effect, in renal graft survival ......................... 699(D), 775
Cephalosporins, third-generation and IHA ............... 202(E), 266, 269
Chimerism, demonstration of in GVHD after transfusion ......................................................... 358
Chronic granulomatous disease ................................. 690(L), 691(L)
Chronic myelogenous leukemia and unrelated-donor marrow transplantation ................................. 180
Classical pathway of complement-mediated lysis .......... 430
CMV, see cytomegalovirus
Coagulation, control of ............................................. 580
Cobalamin ............................................................. 764
Cold agglutinin-associated autoimmune hemolytic anemia ................................................. 790(L)
Cold hemagglutinin disease ..................................... 790(L)
Collections, blood group terminology and .................. 677

Complement testing direct antitogulin test and ................. 304
immediate-spin, hemolytic reaction after ................. 372, 601, 794(E), 814
in infants less than 4 months old .............................. 177
omission of reading after 37°C incubation .................. 304
selection of platelets for refractory patients ............... 295(E), 377, 381, 633, 688(L), 839

Complement activation in determination of biocompatibility of WBC-reduction filters ......................... 557
binding and drug-dependent antibodies .......... 202(E), 266, 269
by anti-M ............................................................. 391(L)
component C3, inhibition of lysis by monoclonal antibodies ......................................................... 430
C4 and CMV antibody titers ........................................ 145
loci for ............................................................... 467
inhibition of classical pathway of activation by monoclonal antibodies ......................................................... 430
levels after filtration of platelets .................................. 328, 557
-mediated lysis, inhibition of by monoclonal antibodies ......................................................... 430
presence on RBCs of HIV-infected patients 426
receptors, analysis of in long-term whole blood donation 51
role in platelet storage characteristics 386
Complementarity-determining region 361
Computers in compatibility testing 794(E), 814
monitoring transfusion practice 253, 260, 648, 787(L), 873(L)
Confidential unit exclusion 465
Confidentiality and use of donor deferral registries 868
Conformational epitopes and antibody response in renal graft survival 699(B), 775
Coronary artery bypass graft surgery, RBC use in 458
Corrected count increment, and transfusion of UVB-irradiated platelets 402
Cost of autologous donation 226
doctor screening tests 696(E), 702
of recombinant FVIII concentrate 291(L)
notification of deferral as donor 696(E), 702
reduction by prospective utilization review 260
Counseling of donors 68, 420, 465, 497(B), 503, 696(E), 702
Cromer blood group system 467, 492(L)
Diethylenetriamine pentaacetic acid 679
Cyclosporin A 699(E), 775
Cytokines, role in febrile nonhemolytic transfusion reactions 594(L)
Cytomegalovirus (CMV) antibody and C4B null genes 145
geographic risk factor for in US Armed Forces blood donors 644
in PBLs of donors, detected by PCR 612
prevalence of markers for in thalassemia patients 509
prevention in bone marrow transplantation and transmission in transfusions by WBC-reduction filters 196(E), 205
Decay-accelerating factor 467, 492(L)
Deferoxamine mesylate 354
DEHP, see diethylhexyl phthalate
Demographic characteristics of US Armed Forces blood donors 644
Demopressin 381
Detailed instructions for authors 92
Diagnosing-related groups (DRGs), 106 and 107, RBC use in 458
Diethyllethamine pentacetic acid 354
Diethylhexyl phthalate (DEHP) 736
Dimercaptosuccinic acid 354
Direct antiglobulin test
performance of in compatibility testing 304
prevalence in AIDS patients 426
Directed donors 292(L), 302(E), 323, 465, 683, 691(L)
Dextranized intravenous coagulation, use of AT III in 580
DNA fingerprinting in diagnosis of transfusion-associated GVHD 766
DNA typing techniques for clonal identification of bacteria 771
Donor(s) apheresis and two-stage procedure for platelet collection 624
autologous blood donation schedule 190(L), 191(L)
bone marrow 231
cost of 226
crossover of blood from to general inventory 683
deferral of 1(E), 17, 689(L)
effect of oral iron supplementation in 162, 788(L), 789(L)
effectiveness of notification process for 696(E), 702
elderly as 1(E), 17, 689(L)
eythropoiesis in 441
eythropoietin levels in 162, 788(L), 789(L)
fibrin glue collection in 641
hemodynamics in 17, 689(L)
iron stores in 162, 788(L), 789(L)
preoperative in high-risk patients 1(E), 17, 689(L)
versus perioperative hemodilution 226
reactions in and safety of 1(E), 17, 689(L)
use of blood drainage collection and transfusion device in 742
bone marrow autologous, transfusion of marrow-derived RBCs in 231
standards for 299(B)
unrelated 180
counseling of 68, 420, 465, 497(B), 503, 696(E), 702
cytokine, role in febrile nonhemolytic transfusion reaction 594(L)
deferral and ICL 800(E)
confidential unit exclusion 465
degree of understanding of hepatitis B surface antigen positivity in 696(E), 702
effectiveness of notification process for 696(E), 702
numbers of in AABB Institutional Membership questionnaire 683
of high-risk patients as 1(E), 17, 689(L)
ratio for gastrointestinal illness 191(L)
registries 868
related, irradiation of blood and risk of GVHD from 797(B), 818
relationship with blood collection facility 465, 696(E), 702
response to anemia screening
ALT 492(L), 760
bacteria infections in 191(L), 397(E), 654
568, 663, 667, 673, 850
CMV 145, 196(E), 205, 272, 509, 612, 644
cost of 696(E), 702
effect of direct versus indirect questions on high-risk behavior for HIV 446
HCV antibody 134, 191(L), 215, 408, 415, 420, 465, 492(L), 509, 548, 644, 683, 805, 824
hepatitis B surface antigen ........................................... 89(L), 134, 215, 509, 644, 683, 696(E), 702, 760, 797(G), 818, 868
hepatitis B core antigen, antibodies to .................................. 492(L), 644, 709(L), 696(E), 702, 760
history of pregnancy .......................................................... 589
HIV .............................................................................. 104, 134, 292(L), 381, 398, 446, 465, 497(G), 503, 509, 683, 707, 797(G), 818, 868, 873(L)
HIV-2 antibody by tests for anti-HIV-1 .................................. 398, 509, 873(L)
HTLV-I/III .......................................................................... 68, 89(L), 295(E), 377, 593(L), 381, 509, 513, 593(L)
ICL .................................................................................. 800(L)
IgA deficiency ...................................................................... 139
privacy of ........................................................................ 446
syphilis .............................................................................. 292(L)
Y. enterocolitica .................................................................. 191(L), 850
safety .................................................................................. 23, 51
selection of for transfusions to refractory patients .............. 633, 859
single-donor RBCs for use in pediatric surgery patients ....... 747
unrelated and risk of GVHD from .................................... 358, 691(L)
US Armed Forces .................................................................. 644
Drainage collection and transfusion device ...................... 742
DRGs, see diagnosis-related groups
Drug absorption mechanism ............................................. 202(E), 266, 269
Drug-cell interactions .......................................................... 554
Drug-dependent antibodies ................................................. 202(E), 266, 269, 554
Drug-induced immunity .......................................................... 554
Duffy blood group system .................................................. 304, 814, 848

Editorial policy on use of allogeneic and homologous 88(L), 397(E), 494(L), 695
ISBT blood group terminology .................................................. 677

Education of donors .................................................................. 465, 696(E), 702
about TRALI ........................................................................ 589
and notification of deferral as donors for patients with hepatitis B surface antigen positivity ............. 696(E), 702
in appropriate use of autologous donations .................. 562
red cell terminology .............................................................. 88(L), 492(L), 593(L), 677
ELA, see enzyme-linked antigenantibody test
ELAT, see enzyme-linked antiglobulin test ............................. 794(E), 814
Electronic compatibility test ...................................................... 677
Electronic data processing equipment, blood group terminology suitable for use in .............................................. 677
Electronmicroscopic examination of WBC-reduction filters 450
ELISA, see enzyme-linked immunosorbent assay
Endotoxin production by Y. enterocolitica ......................... 658
Enterobacter agglomerans .......................................................... 86(L), 221
Enterobacter cloacae ................................................................ 790(L)
Enterococcus faecalis .............................................................. 742, 790(L)
Enzyme immunoassay (ELIA), HCV antibody ....................... 191(L), 408, 415, 420, 492(L), 805
Enzyme-linked antigenantibody test (ELAT) and RBC-bound IgG ......................................................... 426
Enzyme-linked immunosorbent assay (ELISA) ................. 494(L), 618
Epsilon aminocaproic acid ....................................................... 295(L), 377, 381
Errors, transfusion, source of .................................................. 601
Enyrophyosis after autologous blood donation ...................... 441
effect of oral iron supplementation on .................................. 162, 788(L), 790(L)
Enyrophyoestin levels in autologous donors .......................... 162, 788(L), 789(L), 441
role in bone marrow transplantation ...................................... 272
Escherichia coli effect of transfusion on translocation of after burn injury ........................................... 312

gastrointestinal illness and donor deferral ................................ 191(L)
GCSF, see granulocyte-colony-stimulating factor
Gender and

Factor VIII (FVIII) antibodies and IVIG therapy ...................... 361
concentrates and HCV transmission ...................................... 824
cost of manufacture of .......................................................... 291(L)
production of ................................................................. 291(L), 755
purity of ............................................................................ 291(L)
risk of HIV transmission in ................................................... 707
viral infectivity of vapor-heated .............................................. 134
levels in cryoprecipitate after room-temperature
and 1 to 6°C storage .......................................................... 340
Factor IX complex and HCV transmission ......................... 824
Factor XI concentrate, preparation of ...................................... 861
Factor VIII concentrate .......................................................... 861
WBC-reduction activation of platelets by ................................ 500(E), 529
biocompatibility of ................................................................ 557
column versus flatbed ........................................................... 450
cotton wool filters .................................................................. 328
degree of WBC removal in .................................................... 129, 450
enumeration of WBCs after filtration .................................. 565
in removal of activated platelets ............................................ 500(E), 529
bacteria .............................................................................. 597(E), 654, 658, 663, 667, 673
physicochemical characteristics and mechanisms of .......... 450
prestorage, effects of .......................................................... 148, 192(L), 334, 787(L)
prevention of CMV disease .................................................... 196(E), 205
transfusion-associated GVHD .............................................. 102(E), 169, 272
removal of activated platelets by ........................................ 500(E), 529
verification of correct use of at bedside .................... 192(L)
Flow cytometry, detection of platelet activation ................. 500(E), 529, 534
Food and Drug Administration regulation of biologic products .......................................................... 299(E)
Folic acid ............................................................................ 764
French, risk of transfusion-associated GVHD in .................... 691(L)
Fresh-frozen plasma (FFP)
monitoring use of .............................................................. 253, 260, 648, 787(L), 873(L)
number reported in AABB Institutional Membership Questionnaire .................................................. 683
preparation of IgA-deficient .................................................... 139
screening for HCRNA in ........................................................ 420
storage temperature and fibrinogen levels in ........................ 755
use in ABO-unmatched liver transplantation ..................... 829
use in heart and heart-lung transplants ..................................... 57

Gastrointestinal illness and donor deferral .............................. 191(L)

Spanish
affect of specimen handling and storage on RNA detection ... 420
geographic risk factors for in US Armed Forces blood donors ... 644
partitioning of during Cohn-Oncley fractionation of plasma ... 824
prevalence of markers for in blood donors in Guadeloupe ... 760
hemophiliacs and von Willebrand patients ... 134
thalassemia patients ... 509
risk of transmission by cryoprecipitate ... 824
IVIG ... 824
vapor-heated FVIII concentrate ... 134
supplemental testing effect of specimen handling/storage in detection of RNA ... 420
increased detection of antibody with 191(L), 408, 415, 420, 492(L), 548, 805
HES, see hydroxyethyl starch ... 855
Histocompatibility ... 699(E), 775
HIV, see human immunodeficiency virus
HLA antibody, detection of for selection of platelets for refractory patients ... 633, 839
epitope matching in renal transplants ... 699(E), 775
haplotypes and GVHD ... 302(E), 323, 358, 691(L)
frequency in ethnic groups ... 358, 691(L)
typing in diagnosis of transfusion-associated GVHD ... 766
Homologous blood transfusion, see allogeneic
Homology ... 394(E), 494(L), 695
HTLV-I/II, see human T-lymphotropic virus type I/II
Human immunodeficiency virus type 1 (HIV-1) and directed donations ... 292(L)
behavioral risks for among blood donors ... 446
coinfection with HTLV-I/II ... 513
latent infection ... 104, 497(E), 503
levels of platelet-associated immunoglobulins in ... 157
-negative AIDS ... 800(E)
prevalence of markers for in thalassemia patients ... 509
RBC-bound IgG levels in infection ... 426
risk of transmission by plasma-derived factor concentrates ... 707
platelet concentrates ... 295(E), 377, 381
vapor-heated FVIII concentrate ... 134
seronegative period of latent infection ... 104, 497(E), 503
transmission to sexual partners ... 104, 497(E), 503
Human immunodeficiency virus type 2 (HIV-2) antibody detection by tests for HIV-1 antibody ... 398, 873(L)
antigen testing ... 873(L)
prevalence in thalassemia patients ... 509
United States blood donors ... 398
Human T-lymphotropic virus type I/II (HTLV-I/II) coinfection with HIV ... 513
look-back ... 68
prevalence in blood donors in Northern Marianas ... 593(L)
in Solomon Islands ... 89(L)
thalassemia patients ... 509
transfusion-transmitted ... 68, 89(L), 295(E), 377, 381, 509, 513, 593(L)
Hybrid genes ... 467
Hydroxyethyl starch (HES) ... 855
Hypotonicity and red cell storage ... 37

I

ICL, see idiopathic CD4+ T-lymphotopenia ... 800(E)

Idiopathic CD4+ T-lymphotopenia ... 800(E)
Idiopathic thrombocytopenic purpura (ITP) ... 235, 361
Idiotype ... 361
Idiotype ... 361
IgA levels in IgA-deficient donors after serial plasmapheresis ... 139
monoclonal antibodies, serologic activity and molecular structure ... 239
IgG
IgG4, role in anaphylaxis ... 576
number of molecules on RBCs in AIDS patients ... 426
IIA, see immune hemolytic anemia
il antigens ... 572, 607, 790(L)
Immune complex circulating, in AIDS patients ... 426
disease and anti-idiotypic antibodies ... 361
mechanism and drug-dependent antibodies ... 202(E), 266, 269
presence in renal patients with TTP ... 710
Immune globulin molecule, structure of ... 361
Immune hemolytic anemia (IIA), drug-induced ... 202(E), 266, 269
Immune modulation
and ABO mismatching of platelet transfusions ... 688(L)
anti-idiotypic antibody to T-cell receptor and GVHD ... 719
long-term whole blood donation ... 51
microbial translocation after transfusion ... 312
number of natural killer cells after surgery, anesthesia, and transfusion ... 517
protein column A apheresis ... 210
transfusion ... 27, 31, 312, 318, 629, 691(L)
approaches to ... 299(E)
blocking response to transfusion ... 429
HES in ... 855
in renal graft survival ... 699(E), 775
network theory of ... 361
Immune response
in vitro tests for ... 699(E), 775
regulation of and anti-idiotypic antibodies ... 361
Immune thrombocytopenic purpura and protein column A apheresis ... 210
Immunoglobulin levels in AIDS patients ... 426
quantisation of platelet-associated immunoglobulins ... 157, 235
Immunotherapy ... 42, 599(E), 629
Inab phenotype ... 467
Incentive-based donor recruitment strategies ... 818
Indirect antiglobulin test and detection of antibodies reacting at 37°C ... 304
Infants less than 4 months old, antibody development in ... 177
Infection, postoperative and transfusion ... 27, 318, 517
Information for authors ... 92
Information systems in monitoring transfusion practice ... 253, 260, 648, 787(L), 873(L)
In(Lu) gene ... 607
Interleukin-1β ... 594(L)
Interleukin-2 ... 299(E)
Interleukin-3 ... 272
International Society of Blood Transfusion (ISBT)
and red cell antigen nomenclature ... 492(L), 677
blood group terminology suitable for use in electronic data processing equipment ... 677
working party for quality control of platelets ... 500(E), 529
Intravenous immune globulin (IVIG) number reported in AABB Institutional Membership Questionnaire ... 683
technique and complications ... 286
Intravenous immune globulin and anti-idiotypic antibodies ... 361
HCV transmission ............................ 824
use in autoimmune hemolytic anemia ............................ 173
idiopathic thrombocytopenic purpura ............................ 235, 361
patients with FVIII antibodies ............................ 361
Inventory management, prestorage irradiation of RBCs and iron supplementation in autologous donors ............................ 162, 788(L), 789(L)
Irradiation gamma effect on RBCs ............................ 246
prevention of transfusion-associated GVHD ............................ 102(E), 169, 180, 272
of blood components from directed and related donors ............................ 302(E), 323, 358, 691(L)
of RBCs before storage ............................ 525
UVA effect on platelets ............................ 541
UVB, effect on platelets ............................ 402
viruses ............................ 121
WBC viability ............................ 109
ISBT, see International Society of Blood Transfusion ............................ 397(E), 494(L), 695
IVIG, see intravenous immune globulin

J
Japanese, risk of transfusion-associated GVHD in random-donor blood ............................ 358, 691(L)

K
Kell blood group system antibodies ............................ 304, 790(L), 814, 848
gen cloning and proteins of ............................ 98(E), 467
McLeod phenotype and chronic granulomatous disease ............................ 691(L)
Kidd blood group system ............................ 304, 467, 607, 814, 874(L)
Kidney transplantation ............................ 699(E), 775

L
LAK cells, see lymphokine-activated killer cells
Legal issues and use of donor deferral registries ............................ 868
Length of hospital stay and cardiac bypass graft surgery (DRGs 106 and 107) ............................ 458
hemoglobin concentration after total hip arthroplasty ............................ 63
postoperative infections ............................ 27, 318, 517
transfusion in spinal surgery ............................ 517
Leukapheresis, large-volume ............................ 729, 733
Leukemia, expression of Tn in ............................ 834
Lipid peroxidation in stored RBCs ............................ 354
Literature review on autologous transfusion ............................ 286
Liver transplantation ............................ 829
Look-back for HTLV-1/2 ............................ 68
ICL ............................ 800(E)
Louisiana, southern, prevalence of HCV in blood donors ............................ 415
Lutheran blood group system ............................ 607
Lymphocyte effect of gamma radiation on ............................ 102(E), 169
mechanism of removal by WBC filters ............................ 450
receptor and subset analysis in lgA-deficient donors after serial plasmapheresis ............................ 139
long-term whole blood donors ............................ 51
Lymphokine-activated killer (LAK) cells, cryopreservation of ............................ 42
Lymphoma expression of Tn in ............................ 834
PBSC transplantation in ............................ 729, 733

M
Major histocompatibility complex and GVHD ............................ 302(E), 323, 358, 691(L)
Malondialdehyde ............................ 354
Mannitol, effect in quenching of oxygen radicals in platelet storage ............................ 541
Manuscript preparation requirements ............................ 92
McLeod phenotype and chronic granulomatous disease ............................ 691(L)
Media platelet storage ............................ 3(E), 9, 152, 386, 435
RBC ............................ 37
Metal chelators, role in RBC storage ............................ 354
Methyldopa and drug-dependent antibody production ............................ 202(E), 266, 269
Microbial translocation, effect of transfusion after burn injury ............................ 312
Microvesicles, expression of blood group antigens on during RBC storage ............................ 848
Military blood donors ............................ 644
MNS blood group system ............................ 391(L), 467, 629, 814, 848
Molecular biology of blood group genes ............................ 98(E), 467
techniques and RBC antigen terminology ............................ 88(L), 492(L), 593(L), 677
Monoclonal antibodies anti-C3d and anti-C3c and complement-mediated lysis inhibition ............................ 430
in B-cell lymphoma and leukemia idiootype determination ............................ 361
in detection of platelet activation and GMP-140 ............................ 3(E), 9, 386, 500(E), 529
RBC antigens ............................ 86(L)
Tn ............................ 834
serologic activity and molecular structure of ............................ 239
Monocyte
effect of HES on ............................ 855
mechanism of removal by WBC filters ............................ 450
receptor analysis in long-term whole blood donors ............................ 51
Morganella morganii ............................ 790(L)
Mortality, in-hospital, in cardiac bypass graft surgery (DRGs 106 and 107) ............................ 458
Motivation of donors ............................ 797(E), 818
Multilocus DNA fingerprinting in diagnosis of transfusion-associated GVHD ............................ 766
Multiparous donors and TRALI ............................ 589
Mycobacterium tuberculosis ............................ 569
Myelodysplasia, expression of Tn in ............................ 834

N
Nagotte hemocytometer ............................ 565
NANBH, see non-A,non-B hepatitis
National Blood Policy ............................ 465
National Hemophilia Foundation (NHF) abstracts ............................ 484
National Marrow Donor Program ............................ 180
Natural killer cells, number after surgery, anesthesia, and transfusion ............................ 857
n-butyryl-tri-n-hexyl-citrate (BTHC) ............................ 736
Neonatal patients antibody development and compatibility testing in prevention of CMV in ............................ 177
use of single-donor RBCs for in surgery ............................ 747
Neutrophil-specific antibody and TRALI ............................ 589
NPLD ............................ 845
Nomenclature blood group suitable for use in electronic data processing equipment ............................ 677
IP ............................ 86(L), 593(L)
red cell antigen, general ............................ 88(L), 492(L), 677
weak D antigen ................................................. 86(L), 593(L)
Non-A, non-B hepatitis (NANBH) detection of HCV antibody in ........................................ 548, 805
prevalence in hemophilia patients .......................... 134
transfusion recipients ........................................... 215
von Willebrand patients ........................................ 134
Nonsecretor status, classification of by ELISA ....... 618
O
Open canalicular system ....................................... 46
Orthopedic surgery and acquired AT III deficiency 580
Oxygen-free radical formation in stored RBCs ........... 354
Oxygen tension and radical formation in platelet storage 541
P
P blood group system .......................................... 391(L), 607, 847(L)
PADGEM, see alpha-granule membrane protein-140
Paroxysmal nocturnal hemoglobinuria .......................... 467
Passive agglutination mechanism and drug-dependent antibodies ........................................... 202(E), 266, 269
PBSC, see peripheral blood stem cells
PCR, see polymerase chain reaction Pediatric surgery patients and use of single-donor RBCs 747
Penicillin and IHA ............................................ 202(E), 266, 269
Pepidemic surgery patients and use of single-donor RBCs 747
drome and renal graft survival .............................. 699(E), 775
Peripheral blood lymphocytes, detection of CMV in by PCR ........................................... 612
Peripheral blood stem cells (PBSC) ..................... genetic fingerprint of in transfusion-associated GVHD
Plasma donor/recipient type for in ABO-unmatched liver transplant................................. 766
exchange in renal patients with TTP ......................... 729, 733
membrane changes during .................................. 744
platelet-rich plasma method ................................. 272, 299(E)
ph, role of acetate in maintenance of in platelet storage ........................................... 386
Phosphate and red cell storage ................................ 152
Photosensitizers in virus inactivation .......... 121
Platelet(s)
addition of amphotericin B and ................................ 848
as platelet storage media ........................................ 3(B), 9, 152, 386, 435
autologous albumin preparation from by heat ................ 349
Cohn-Oncley fractionation of and HCV transmission ...................................................... 824
-derived factor concentrates and risk of HIV in ....... 707
donor/recipient type for in ABO-unmatched liver transplant ........................................... 829
donor/recipient type for in ABO-unmatched liver transplant ........................................... 829
effect of amphotericin B in .................................... 7(B), 46
effect on storage lesion ........................................... 386
glycoprotein Ib and IIb-IIIa levels after .................. 386
membrane changes during .................................. 113
membrane changes during .................................. 113
metabolic activity during ....................................... 435
role of oxygen quenchers in .................................. 435
platelet additive solution ...................................... 386
physiology and storage lesion ................................ 386
quality assurance in ............................................. 386
recovery after ....................................................... 386
storage in ......................................................... 386
UVB irradiation ................................................... 402
UVB irradiation ................................................... 402
wavelengths after ................................................. 386
Z
Zinc physiological role ................................. 392, 500(B), 504
after activation 3(E), 9, 113, 386, 435, 500(E), 529, 534

transfusion by two-stage procedure 624
cotton wool filtration 328
prestorage WBC reduction 148, 334, 787(L)
pretransfusion incubation at 37°C 715
storage in non-DEHP-plasticized container 736
platelet additive solution 435
UVB irradiation of WBC-reduced components 402
of GMP-140-positive platelets 3(E), 9, 386, 500(E), 529

transfusion (and)

after 37°C incubation 715
anaphylactic reaction due to anti-Ch in compatibility testing versus HLA-matching for refractory patients 295(E), 377, 381, 633, 688(L), 839
effect of amphotericin B 7(E), 46
guidelines for 253, 260, 295(E), 377, 381, 648, 787(L), 873(L)
in lymphoma patients after large-volume leukapheresis 729, 733
monitoring of platelet use 253, 260, 648, 787(L), 873(L)
number of reported in AABB Institutional Membership Questionnaire 683
prophylactic versus therapeutic 295(E), 377, 381
survival of activated platelets 3(E), 9, 113, 386, 435, 500(E), 514, 529
survival of heart and heart-lung transplants 57, 618

use in bone marrow transplantation 272
heart and heart-lung transplants 57
UVB irradiation of virus inactivation in WBCs in after WBC filtration 129, 148, 334, 450, 565, 787(L)
yield after preparation 3(E), 9, 113, 435
prestorage WBC removal 148, 334, 787(L)
Platelet activation-dependent granule to the external membrane (PADGEM), see alpha granule membrane protein-140
Plasticizers, role in platelet storage 386, 736
Polymerase chain reaction (PCR) detection of CMV 612
CMV in 766
HCV 408, 420, 805
hepatitis B variants 215
HIV 104, 497(E), 503
Y. enterocolitica 830
effect of specimen handling and storage in 420
false-negative results due to glove powder 83
Postoperative blood salvage 286, 742
Potassium and RBC storage 37
level in plasma after irradiation of RBCs 246, 525
Preoperative autologous blood donation annotated bibliography 286
Pretransfusion testing 304, 794(E), 814
Prostate-specific antigen 304
Protein column Apheresis 210
Proteins, Kell system 98(E), 467
P-selectin, see alpha granule membrane protein-140
Ponaran 541

Quality assurance and transfusion guidelines 253, 260, 648, 787(L), 873(L)
computer and monitoring of transfusion practice 253
in platelets 500(E), 529

R

Reactions during donation 23
transfusion anaphylactic 576
and TRALI 589
delayed hemolytic 794(E), 814
febrile, nonhemolytic 594(L)
hemolytic 572, 601
to salvaged RBCs 742

Reagents monoclonal anti-C3d and anti-C3c 430
anti-D 86(L)
anti-IgA, serologic and molecular structure 239
in B-cell lymphoma and leukemia idiotype determination 361
detection of platelet activation and GMP-140 3(E), 9, 386, 500(E), 529
Tn 834
inhibition of complement-mediated lysis of sensitized RBCs by 430
Recombinant immunoblot assay (RIBA), anti-HCV 191(L), 408, 415, 805
Recruitment of donors 797(E), 818, 868
Red cell(s)
additive solutions and storage of frozen-thawed blood group genes 467
- bound IgG levels in AIDS patients 426
cation content after irradiation 246
department of from blood drainage collection and transfusion device 742
detection of characteristics of from blood drainage collection and transfusion device 246
complement activation products in after WBC filtration 557
discoloration due to Y. enterocolitica 199(E), 221
in inhibition of complement-mediated lysis on sensitized RBCs by 430
RBCs in 3(E), 9, 386, 500(E), 529

Q

non-computer-dependent monitoring of transfusion practice 260
WBC-reduced components 129, 192(L), 450, 565
Quenchers of reactive oxygen species in virus inactivation of platelets 541
Quercetin, role as quencher of oxygen radicals in platelet storage 541
Quinine and drug-dependent antibody production 202(E), 266, 269
Quinine and drug-dependent antibody production 202(E), 266, 269
expression of blood group antigens on microvesicle membranes during hypotonicity, effect of lipid peroxidation in media of from persons with In(Lu) gene of frozen-thawed oxygen-free radical formation in phosphate, effect of potassium, effect of prestorage irradiation of Y. enterocolitica in with WBC-reduction filters undergoing autologous blood donation sensitization to cefotetan single-donor, in pediatric surgery patients survival after prestorage irradiation of from persons with In(Lu) gene transfusion and cancer recurrence and survival and survival of heart and heart-lung transplants donor/recipient type in ABO-unmatched liver transplant number of reported in AABB Institutional Membership Questionnaire use in bone marrow transplantation in heart and heart-lung transplants in liver transplantation in spinal surgery in total hip arthroplasty monitoring of in transfusion practice viability of frozen-thawed RBCs after 4°C storage WBC removal and enumeration of WBCs in after Y. enterocolitica in Registries, donor deferral Remuneration of donors Renal graft survival Reporting of transfusion errors Research efforts in platelet preservation and storage Retrovirus Epidemiology Donor Safety Retroviruses, inactivation of Rh blood group system RIBA, see recombinant immunoblot assay Rodgers and Chido antigens, genetics of Safety of the blood supply Salvia sclarea Schedule of optimal preoperative collection of autologous blood Scianna blood group system Secretor status, classification by ELISA Series, blood group terminology and Serology and blood group genes Sicily, implementation of HTLV-I screening in thalassemia patients Social learning theory and donor recruitment Social mission-based donor recruitment strategies Sodium ascorbate, as quencher of oxygen radicals in platelet storage in RBCs after irradiation Solomon Islands, HTLV-I prevalence in blood donors Solvent/detergent treatment in factor XI preparation Standards of the AABB bone marrow processing compatibility testing for infants less than 4 months old immediate-spin development of modification of notification of changes in storage of cryoprecipitate after thawing Staphylococcus epidermidis Storage of cryoprecipitate after thawing RBCs after irradiation lesion in platelets media platelet red cell Superse discocyte, as quencher of oxygen radicals in platelet storage Supplemental testing for HCV antibody Survival and transfusions Survey of AABB Institutional Members Surgery bleeding and efficacy of tranexamic acid blood loss in total hip arthroplasty blood use in cardiac bypass graft surgery (DRGs 106 and 107) orthopedic surgery effect of anesthesia and transfusion on postoperative infection in efficacy of postoperative autologous blood drainage collection and transfusion device orthopedic and treatment of acquired AT III deficiency blood use in use of blood drainage collection and transfusion device in predictors of postoperative infection in orthopedic use of autologous transfusions in Survey of AABB Institutional Members Syphilis and directed donations Swirl, as a measure of platelet shape change T-cell depletion and survival in bone marrow transplantation T-cell levels in ICL T-cell receptor, anti-idiotypic antibody to and GVHD Temperature modulation and fibrinogen content in cryoprecipitate T-cell storage Terminology allogeneic and homologous RBC antigens standardized, for weak D Tetanus toxoid immunization and anti-idiotypic response Thalassemia patients, prevalence of viral markers in Thorbin, role in platelet storage Thrombotic thrombocytopenic purpura (TTP) Tn TRALL, see transfusion-related acute lung injury Tranexamic acid TRANSFUSION, editorial policy on terminology
allogeneic and homologous.............. 397(E), 494(L), 695
ISBT blood group terminology......... 677
RBC antigens......................... 86(L), 88(L), 492(L), 593(L), 677

Transfusion
and postoperative infection........... 27, 318, 517
and survival
after burn injury..................... 312
in cancer............................ 31, 829
in heart and heart-lung transplants... 57, 618
-associated deaths
HIA after cefotetan administration...... 202(E), 266, 269
Y. enterocolitica..................... 199(E), 221
cancer recurrence and survival and...
complications
associated with vapor-heated...
FVIII concentrates................. 134, 291(L), 707, 755, 824
bacterial contamination............... 3(B), 9, 86(L), 191(L), 199(E), 221,
381, 344, 597(E), 654, 658, 663, 667, 741, 771, 850
GVHD and
anti-idiotypic antibody to T-cell receptor... 719
blood from unrelated donors in Japan.... 358, 691(L)
bone marrow transplants............. 180, 272
generic fingerprinting in diagnosis of... 766
potential risk of in ethnic groups.......
in random transfusion.................. 358, 691(L)
transfusion of blood from related...
and directed donors................... 302(E), 323, 691(L)
unrelated-donor marrow transplants.... 180, 272
WBC-reduced components............. 102(E), 169, 272
postoperative infection risk.......... 27, 318, 517
reactions
anaphylactic due to anti-Ch............ 576
bacteremia as a source of............ 771
delayed hemolytic after immediate-spin crossmatch... 794(E), 814
febrile nonhemolytic, pathogenesis of... 594(L)
hemolytic................................ 572, 601
to salvaged RBCs..................... 742
related acute lung injury (TRALI)...... 589
testng before.......................... 504, 794(E), 814
-transmitted diseases
CMV...................................... 145, 196(E), 205, 272, 509, 612, 644
HCV...................................... 134, 191(L), 215, 408, 415, 420, 465,
492(L), 509, 548, 644, 683, 805, 824
hepatitis B.............................. 89(L), 134, 215, 492(L), 509, 644,
683, 696(E), 702, 760, 797(E), 818, 868
HIV-1 - 134, 292(L), 381, 446, 465, 497(E), 503, 509, 683, 707
HIV-2................................. 398, 509, 873(L)
HTLV-II................................. 68, 89(L), 295(E), 377, 381, 509, 513, 593(L)
NANBH................................. 134, 215, 548, 805
reduction of by autologous fibrin glue.... 641
syphilis.................................. 292(L)
Y. enterocolitica....................... 3(B), 9, 191(L), 199(E), 221, 597(E),
654, 658, 663, 667, 673, 850
trigger
platelets............................... 295(E), 377, 381
RBCs..................................... 648

Transplantation
across ABO lines
donor/recipient RBC and plasma type in... 829
use of synthetic A substance in........ 618
bone marrow
autologous............................. 231
blood use in........................... 272
effect of amphotericin B in........... 7(E), 46
erythropoietin in...................... 272
from unrelated donors.................. 180
prevention of CMV transmission in...... 272
processing standard................... 629(E)
role of blood bank in.................. 272, 295(E)
T-cell depletion and survival in.......... 180
transfusion of marrow-derived RBCs after donation in... 231
kidney, evaluation of role of HLA-DP in... 699(E), 755
heart.................................. 57, 618
heart-lung.............................. 57
HLA epitope matching in.............. 699(E), 755
liver, ABO- unmatched.................. 829
PBSC.................................... 272, 729
perioperative use of blood in........... 57, 618
use of CMV-seronegative blood in...... 196(E), 205
use of synthetic A substance in........ 618

Trial to Reduce Alloimmunization to Platelets (TRAP)........... 688(L)

TP, see thrombotic thrombocytopenic purpura
Tumor necrosis factor
levels after protein column Apheresis ........................................ 210

U

Ultraviolet-A (UVA) irradiation, psoralen and quenchers in virus inactivation of platelets .................................................. 541
Ultraviolet-B (UVB) irradiation
effect on platelets .................................................. 402
WBC viability .................................................. 109
virus inactivation .................................................. 121
umbilical cord blood PBSC collection from .................................. 180
Undertransfusion reviews ........................................ 253, 260, 648, 787(L), 873(L)

V

Vaccines, anti-idiotypic antibodies as ........................................ 361
Vapor-heated FVIII concentrate ........................................ 134
Venous thrombosis and AT III deficiency ...................................... 580
Videotape presentation and recruitment of high school blood donors ........................................ 797(E), 818
Viral disease and C4B null genes ........................................ 145

Virus, inactivation
benzoporphyrin monoacid ring A ........................................ 121
during Coln-Oncley fractionation of plasma .................................. 824
in clotting factor concentrates ........................................ 291(L), 707, 755, 861
in platelets by psoralen and UVA in the presence of quenchers ........................................ 541
in vapor-heated FVIII concentrate ........................................ 134
Volunteering and the blood supply ........................................ 292(L), 465, 797(E), 818
von Willebrand antigen levels in renal patients with TTP ........................................ 710
disease, risk of viral infection from vapor-heated FVIII concentrate ........................................ 134
factor levels after prestorage WBC reduction of platelets ........................................ 148

W

WBC, see white cell
Western blot, HIV testing ........................................ 398, 497(E), 503
White cell (WBC) and platelet storage lesion .................................. 334

and phagocytosis of Y. enterocolitica ........................................ 597(E), 654, 658, 663, 667, 673
effect of HES on ........................................ 835
enumeration after filtration for removal of .................................. 129, 192(L), 450, 565
filters
activation of platelets by ........................................ 500(E), 529
and mechanisms of removal of ........................................ 450
biocompatibility of ........................................ 557
inactivation in platelets by UVB irradiation .................................. 402
loss of viability after UVB irradiation ........................................ 109, 402
number in platelets after preparation ...................................... 3(E), 9, 113
-reduced components, use in thalassemia patients ........................................ 509

WEC, see white cell

Wester blot, HIV testing

White cell (WBC)

Wright antigens ........................................ 87(L), 629

X

Xenograft ........................................ 397(E), 494(L), 695

Y

Yersinia enterocolitica ........................................ 3(E), 9, 191(L), 199(E), 221, 597(E), 654, 658, 663, 667, 673, 850

Z

Zygosity ........................................ 88(L)